'Radicava,' an oral drug for the treatment of amyotrophic lateral sclerosis (ALS), is expected to be commercialized in South Korea.

Sources said that Mitsubishi Tanabe Pharma Korea's Radicava (edaravone) is under consideration for domestic approval. The drug is a treatment for ALS, formerly known as Lou Gehrig's disease.

Radicava is an oral suspension. It can reduce patient burden by lowering the number of hospital visits and pain compared to conventional drugs designed for intravenous (IV) injection.

Radicava received accelerated approval designation from the U.S. Food and Drug Administration (FDA) in October 2019. The drug was approved in May 2022.

It h